

DOCKET NO.: ALLE0047-101 (17006 CON2)
U.S. Serial No. 09/845,512

PATENT

Listing of Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-13. (Cancelled)

14. (Currently amended) A method of treating a human suffering from a dystonia, the method comprising the steps of

administering up to 1,000 units of a botulinum toxin type A to a human spasm suffering from a dystonia until the human experiences a loss of clinical response to the administered botulinum toxin type A, as determined by a failure of the administered botulinum toxin type A ~~to achieve a marked reduction of or~~ to substantially alleviate a symptom of the dystonia; and

administering up to 300 units of a botulinum toxin type E to the human after the human exhibits a loss of clinical response to the administration of botulinum toxin type A to thereby again achieve a ~~marked reduction of or~~ substantial alleviation of a symptom of the dystonia.

15. (Cancelled)

16. (previously presented) The method of claim 14, wherein the amount of botulinum toxin type A is less than 500 units.

17. (Cancelled)

18. (Previously presented) The method of claim 14, wherein the amount of botulinum toxin type A administered to the human is from 80 units to 460 units, and the amount of botulinum toxin type E administered to the human is less than 300 units.

DOCKET NO.: ALLE0047-101 (17006 CON2)
U.S. Serial No. 09/845,512

PATENT

19. (Currently amended) A method of treating a patient suffering from a cervical dystonia, the method comprising the steps of

administering up to 1,000 units of a botulinum toxin type A to a human patient suffering from a dystonia until the human experiences a loss of clinical response to the administered botulinum toxin type determined by a failure of the administered botulinum toxin type A ~~to achieve a marked reduction of~~ or to substantially alleviate a symptom of the dystonia; and

administering up to 300 units of a botulinum toxin type E to the patient to treat the cervical dystonia after the patient exhibits a loss of clinical responsiveness to the administration of botulinum type A.

20. (Cancelled)

21. (Previously presented) The method of claim 19, wherein the amount of botulinum toxin type A is less than 500 units.

22. (Cancelled)

23. (Previously presented) The method of claim 19, wherein the amount of botulinum toxin type A administered to the patient is from 80 units to 460 units, and the amount of botulinum toxin type E administered to the patient is less than 300 units.

24. (Cancelled)

25. (New) A method of treating a human suffering from a dystonia, the method comprising the steps of

administering a botulinum toxin type A to a human spasm suffering from a dystonia until the human experiences a loss of clinical response to the administered

DOCKET NO.: ALLE0047-101 (17006 CON2)
U.S. Serial No. 09/845,512

PATENT

botulinum toxin type A, as determined by a failure of the administered botulinum toxin type A to substantially alleviate a symptom of the dystonia; and

administering a botulinum toxin type E to the human after the human exhibits a loss of clinical response to the administration of botulinum toxin type A to thereby again achieve a substantial alleviation of a symptom of the dystonia.

26. (New) The method of claim 25, wherein the dystonia is a cervical dystonia.